Skip to content
PubMed This is a summary of 50 peer-reviewed journal articles Updated
Hematology

Thiamine-responsive megaloblastic anemia syndrome: A Patient Guide

At a Glance

TRMA (Rogers syndrome) is an inherited SLC19A2 condition that causes megaloblastic anemia, diabetes, and sensorineural hearing loss. Lifelong high-dose oral thiamine often corrects anemia and improves blood sugar control, but may not reverse hearing loss; ongoing monitoring remains important.

Thiamine-responsive megaloblastic anemia syndrome (TRMA), also known as Rogers syndrome, is an ultra-rare genetic condition that fundamentally changes how the body produces and uses energy. At its core, the condition is an autosomal recessive disorder caused by a mutation in the SLC19A2 gene, which is responsible for creating a specialized “doorway” or transporter that moves thiamine (Vitamin B1) into cells [1]. When these transporters do not function correctly, vital organs—specifically the bone marrow, the pancreas, and the inner ear—become starved for thiamine, even if there is plenty of the vitamin in the diet [2].

This lack of cellular thiamine typically leads to a “classic triad” of medical challenges: megaloblastic anemia, diabetes mellitus, and sensorineural hearing loss [3]. The anemia occurs because blood cells cannot grow properly without thiamine, while the diabetes arises because the pancreas lacks the energy to produce insulin effectively [4]. The hearing loss is caused by the vulnerability of delicate cells in the inner ear to thiamine deficiency [5]. Because these symptoms can appear at different times throughout childhood, early recognition and a clear genetic diagnosis are essential for starting the right treatment [6].

The most encouraging aspect of TRMA is its responsiveness to treatment. While the body’s primary thiamine doorways are broken, giving high-dose oral thiamine allows the vitamin to enter cells through lower-affinity alternative pathways [7]. This lifelong treatment is remarkably effective at correcting the anemia and helping the body manage blood sugar levels, often reducing the need for other medications [8]. Caregivers must never self-adjust or stop thiamine doses, as strict medical supervision is critical. However, because the treatment does not always reverse established hearing loss or protect all systems equally, the focus of care is on starting thiamine early and maintaining it without interruption [9].

Living with TRMA requires a coordinated effort between a family and a multidisciplinary care team. Because the condition affects multiple parts of the body, ongoing surveillance of blood counts, blood sugar, hearing, vision, and heart health is necessary to ensure the treatment remains effective as a child grows [10].

When to seek urgent help: Families should have a clear sick-day plan. If a child with TRMA experiences severe lethargy, inability to keep medication down due to vomiting, rapid/deep breathing, or fainting, they should seek emergency medical care immediately.

While a diagnosis of an ultra-rare condition can feel overwhelming, having a named cause and a clear treatment path provides a roadmap for long-term health and stability [11]. (Note: The bracketed codes throughout this guide refer to published medical studies supporting TRMA care).

Common questions in this guide

What is thiamine-responsive megaloblastic anemia syndrome?
Thiamine-responsive megaloblastic anemia syndrome, also called TRMA or Rogers syndrome, is an ultra-rare inherited disorder caused by changes in the SLC19A2 gene. It prevents cells from taking in thiamine efficiently and commonly affects blood production, blood sugar regulation, and hearing.
What are the main signs of TRMA?
The classic combination is megaloblastic anemia, diabetes mellitus, and sensorineural hearing loss. These problems may begin at different times during childhood, so a child may not have all three when first evaluated.
How does high-dose thiamine help children with TRMA?
High-dose oral thiamine can enter cells through backup transport routes when the main transporter does not work properly. Lifelong treatment often corrects the anemia and helps manage blood sugar, but it may not reverse hearing loss that is already established.
Will thiamine treatment for TRMA need to continue for life?
Yes, thiamine treatment is generally lifelong because the SLC19A2 transport problem remains. Families should not change or stop the dose without medical guidance, even if blood counts or blood sugar improve.
What monitoring and specialists are needed for TRMA?
Ongoing care may include hematology and endocrinology, with regular checks of blood counts, blood sugar, hearing, vision, and heart health. The treating team can tailor the schedule as the child grows and coordinate care across these needs.
When should a child with TRMA receive emergency care?
Seek emergency care for severe lethargy, fainting, rapid or deep breathing, or vomiting that prevents the child from keeping thiamine or other medicines down. Families should discuss a sick-day plan with the treating team before an illness occurs.

Get notified when new evidence is published on Thiamine-responsive megaloblastic anemia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    [Thiamine-responsive megaloblastic anemia or Rogers syndrome: A literature review].

    Lu H, Lu H, Vaucher J, et al.

    La Revue de medecine interne 2019; (40(1)):20-27 doi:10.1016/j.revmed.2018.06.005.

    PMID: 30031565
  2. 2

    Whole exome sequencing identifies a new mutation in the SLC19A2 gene leading to thiamine-responsive megaloblastic anemia in an Egyptian family.

    Amr K, Pawlikowska P, Aoufouchi S, et al.

    Molecular genetics & genomic medicine 2019; (7(7)):e00777 doi:10.1002/mgg3.777.

    PMID: 31144472
  3. 3

    Thiamine-Responsive Megaloblastic Anemia Syndrome Mimicking Myelodysplastic Neoplasm.

    Klötzer C, Schnabel F, Kubasch AS, et al.

    Acta haematologica 2025; (148(4)):380-385 doi:10.1159/000542286.

    PMID: 39467528
  4. 4

    Loss-of-Function Mutation in Thiamine Transporter 1 in a Family With Autosomal Dominant Diabetes.

    Jungtrakoon P, Shirakawa J, Buranasupkajorn P, et al.

    Diabetes 2019; (68(5)):1084-1093 doi:10.2337/db17-0821.

    PMID: 30833467
  5. 5

    Thiamine responsive megaloblastic anemia syndrome: a novel homozygous SLC19A2 gene mutation identified.

    Mikstiene V, Songailiene J, Byckova J, et al.

    American journal of medical genetics. Part A 2015; (167(7)):1605-9 doi:10.1002/ajmg.a.37015.

    PMID: 25707023
  6. 6

    An Endemic Region of Thiamine-Responsive Megaloblastic Anemia Caused by an SLC19A2 c.1223+1G>A Founder Mutation.

    Gurzhikhanova M, Fomenko S, Chekanov N, et al.

    International journal of molecular sciences 2026; (27(14)) doi:10.3390/ijms27146274.

    PMID: 42511616
  7. 7

    Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome.

    Habeb AM, Flanagan SE, Zulali MA, et al.

    Diabetologia 2018; (61(5)):1027-1036 doi:10.1007/s00125-018-4554-x.

    PMID: 29450569
  8. 8

    Relapse of rare diseases during COVID-19 pandemic: bicytopenia in an adult patient with thiamine-responsive megaloblastic anaemia.

    Nouira N, Mansouri R, Tlili R, et al.

    The Pan African medical journal 2020; (35(Suppl 2)):139 doi:10.11604/pamj.supp.2020.35.139.25368.

    PMID: 33193954
  9. 9

    Early thiamine therapy in Rogers syndrome: Systematic review of hematologic, auditory and glycemic outcomes.

    Upadhyay Z, Sudani S, Jain A

    Bioinformation 2026; (22(1)):26-30 doi:10.6026/973206300220026.

    PMID: 41960466
  10. 10

    Multidisciplinary Care of Patients with Inherited Metabolic Diseases and Epilepsy: Current Perspectives.

    Tumienė B, Del Toro Riera M, Grikiniene J, et al.

    Journal of multidisciplinary healthcare 2022; (15()):553-566 doi:10.2147/JMDH.S251863.

    PMID: 35387391
  11. 11

    Survey of patient satisfaction with genetic counseling services in Korea.

    Choi IH, Kim YK, Yang SY, et al.

    Journal of genetic counseling 2025; (34(1)):e1922 doi:10.1002/jgc4.1922.

    PMID: 38769825

This page is for informational purposes only and does not constitute medical advice. The child’s treating team should guide thiamine dosing, monitoring, and urgent-care decisions.